Niagen Bioscience, Inc. (NASDAQ:NAGE) Given Consensus Recommendation of "Buy" by Analysts

Niagen Bioscience, Inc. (NASDAQ:NAGE - Get Free Report) has received a consensus recommendation of "Buy" from the five ratings firms that are currently covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have covered the stock in the last year is $13.22.

A number of analysts have recently weighed in on NAGE shares. HC Wainwright restated a "buy" rating and issued a $11.00 target price on shares of Niagen Bioscience in a research note on Monday, March 17th. Wall Street Zen raised shares of Niagen Bioscience from a "buy" rating to a "strong-buy" rating in a report on Sunday, June 22nd. Roth Capital reaffirmed a "buy" rating and set a $23.00 price objective (up previously from $10.00) on shares of Niagen Bioscience in a report on Friday, June 6th. Finally, Canaccord Genuity Group boosted their target price on Niagen Bioscience from $13.00 to $16.00 and gave the stock a "buy" rating in a research report on Tuesday, June 10th.

Niagen Bioscience Stock Performance

Shares of NASDAQ NAGE traded down $0.18 during midday trading on Monday, reaching $11.08. 1,015,598 shares of the company traded hands, compared to its average volume of 963,481. The stock's 50-day simple moving average is $11.92 and its 200-day simple moving average is $8.02. Niagen Bioscience has a 12 month low of $2.53 and a 12 month high of $14.69. The firm has a market cap of $872.77 million, a PE ratio of 65.18 and a beta of 2.14.

Institutional Investors Weigh In On Niagen Bioscience

A number of hedge funds and other institutional investors have recently made changes to their positions in NAGE. D. E. Shaw & Co. Inc. lifted its stake in shares of Niagen Bioscience by 1,785.9% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,011,290 shares of the company's stock worth $5,365,000 after acquiring an additional 957,665 shares during the period. Arrowstreet Capital Limited Partnership raised its stake in Niagen Bioscience by 288.1% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 662,956 shares of the company's stock valued at $3,517,000 after purchasing an additional 492,148 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Niagen Bioscience by 189.0% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 506,186 shares of the company's stock worth $2,685,000 after buying an additional 331,014 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of Niagen Bioscience in the 4th quarter valued at about $1,647,000. Finally, Renaissance Technologies LLC boosted its holdings in Niagen Bioscience by 68.0% during the 4th quarter. Renaissance Technologies LLC now owns 712,788 shares of the company's stock valued at $3,781,000 after acquiring an additional 288,588 shares during the period. 15.41% of the stock is currently owned by institutional investors and hedge funds.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.